Skip to content

Risk Factor Assessment for Acute Pulmonary Hypertension Crisis

Research on the Clinical Risk Factor Assessment System for Acute Pulmonary Hypertension Crisis and Its Mortality

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07653958
Enrollment
5000
Registered
2026-06-17
Start date
2026-06-17
Completion date
2029-12-31
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension, Pulmonary Hypertension Crisis

Keywords

Pulmonary hypertension, Pulmonary hypertension crisis, Diagnosis, Risk factor

Brief summary

The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are: What are the clinical and hemodynamic features of PHC, and what underlying pathophysiological mechanisms cause it to develop? Can these features be used to diagnostic PHC, predict who is at risk of developing it or dying from it, and develop targeted prevention and treatment of PHC? A multi-center registry platform and biobank will be established to enroll and follow up patients with PH. Clinical data, hemodynamic measurements, and biological specimen will be collected. Risk prediction and early warning tools of PHC will be developed.

Detailed description

Pulmonary hypertension crisis (PHC) is a severe and fatal complication of pulmonary hypertension (PH), characterized by the sudden elevation of pulmonary vascular resistance, acute right hear failure and collapse of systemic circulation. However, PHC currently lacks any internationally accepted definition or diagnostic criteria, and it is still unclear which are the clinical, pathophysiological and molecular risk factors of PHC. This study aims to establish a large clinical cohort of patients with PH, validate the definition of PHC, identify risk factors of PHC occurrence and mortality, and develop tools for the risk-prediction and early-warning of PHC. This is a multi-center, prospective cohort study with a retrospective component for model training. Following national health-information standards, a standardized registry dataset will be established to cover demographics, clinical features, laboratory tests, imaging, and hemodynamic profile. Existing PH cohort databases will be integrated and expanded to a target of 5,000 patients. A subset of cases with right heart catheter parameters (RHC) will be extracted. A multi-center biospecimen management platform will be established. For PHC onset, the investigators will assemble a clinical-molecular-imaging feature set and use convolutional neural networks and tree-based algorithms for feature extraction, then build a cross-modal prediction model using multi-task learning, neural networks, and a Transformer architecture. The model will be prospectively validated and tuned against real-world performance. For PHC mortality, models will be built on patients meeting the new PHC criteria, using 28-day attributable death, all-cause death, and long-term death as endpoints. Models will be trained on a retrospective cohort and then evaluated for accuracy and generalizability on both an internal validation set and an external prospective-cohort validation set.

Interventions

None listed

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Pulmonary hypertension confirmed by mean pulmonary arterial pressure (mPAP) over 20 mmHg measured by right heart catheter * At least once per year of follow-up data collection record

Exclusion criteria

* Patients with missing baseline or follow-up data * Complicated by other diseases with significant influence on survival, such as acute coronary syndrome, malignancy, etc. * Complicated by other diseases with significant influence on hemodynamics, such as sepsis, acute left heart failure, and acute pulmonary embolism, etc. * Receiving medications with significant influence on hemodynamics

Design outcomes

Primary

MeasureTime frameDescription
Pulmonary hypertension crisisFrom enrollment to 3 years after enrollmentCritical increase of pulmonary vascular resistance accompanied by right heart dysfunction and systemic hypoperfusion
28 day mortality attributed to pulmonary hypertension crisisFrom hospitalization to 28 daysDeath attributed to pulmonary hypertension crisis within 28 days of hospitalization

Secondary

MeasureTime frameDescription
All cause mortality within hospitalizationFrom hospitalization to discharge or documented death, whichever is earlier, assessed up to 3 yearsAll cause death within hospitalization
All cause mortality within 3 yearsFrom the diagnosis of pulmonary hypertension crisis to documented death, assessed up to 3 yearsAll cause death within 3 years from the diagnosis of pulmonary hypertension crisis

Countries

China

Contacts

CONTACTRun Dong, MD
dongrun5858@foxmail.com861069155036
PRINCIPAL_INVESTIGATORJinmin Peng, MD

Peking Union Medical College Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 23, 2026